- Home
- SHW vs BMY Comparison
SHW vs BMY Comparison
Compare SHW & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHW
- BMY
- Stock Information
- Founded
- SHW 1866
- BMY 1887
- Country
- SHW United States
- BMY United States
- Employees
- SHW N/A
- BMY N/A
- Industry
- SHW RETAIL: Building Materials
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- SHW Consumer Discretionary
- BMY Health Care
- Exchange
- SHW Nasdaq
- BMY Nasdaq
- Market Cap
- SHW 98.0B
- BMY 110.2B
- IPO Year
- SHW N/A
- BMY N/A
- Fundamental
- Price
- SHW $379.62
- BMY $58.29
- Analyst Decision
- SHW Buy
- BMY Hold
- Analyst Count
- SHW 21
- BMY 14
- Target Price
- SHW $395.29
- BMY $53.92
- AVG Volume (30 Days)
- SHW 2.5M
- BMY 12.1M
- Earning Date
- SHW 10-22-2024
- BMY 10-31-2024
- Dividend Yield
- SHW 0.77%
- BMY 4.12%
- EPS Growth
- SHW 7.52
- BMY N/A
- EPS
- SHW 10.03
- BMY N/A
- Revenue
- SHW $23,053,500,000.00
- BMY $47,435,000,000.00
- Revenue This Year
- SHW $1.35
- BMY $6.54
- Revenue Next Year
- SHW $4.38
- BMY N/A
- P/E Ratio
- SHW $36.99
- BMY N/A
- Revenue Growth
- SHW 0.10
- BMY 5.56
- 52 Week Low
- SHW $272.34
- BMY $39.35
- 52 Week High
- SHW $392.57
- BMY $61.08
- Technical
- Relative Strength Index (RSI)
- SHW 44.34
- BMY 58.63
- Support Level
- SHW $367.35
- BMY $55.82
- Resistance Level
- SHW $391.99
- BMY $58.83
- Average True Range (ATR)
- SHW 7.43
- BMY 1.49
- MACD
- SHW -1.02
- BMY 0.02
- Stochastic Oscillator
- SHW 13.35
- BMY 52.04
About SHW Sherwin-Williams Company (The)
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.